Plain-English translation of NCT07332000 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach called aglatimagene besadenovec — a type of gene therapy delivered directly into the prostate — combined with an oral antiviral medication and standard radiation therapy. The study will compare men who receive this new treatment plus radiation against men who receive radiation alone. Researchers want to understand how the new therapy works in the body and whether it triggers an immune response that helps fight the cancer.
Standard radiation therapy is effective for intermediate-risk prostate cancer, but doctors are looking for ways to improve outcomes and reduce the chance of cancer coming back. This medication is designed to work alongside radiation by helping the body's immune system recognize and attack cancer cells more effectively.
You likely qualify if…
You likely don't qualify if…
If you join the treatment group, you will receive three injections of the new therapy directly into your prostate over several weeks, along with an oral antiviral medication to take at home. You will then begin standard radiation therapy. If you are in the control group, you will receive radiation therapy alone. Throughout the study, you will have blood drawn, provide urine samples, and provide semen samples at various timepoints so researchers can track how the therapy moves through your body and how your immune system responds. The study team will monitor you continuously for any side effects.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States